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Summary
Background Spinal stereotactic body radiation therapy (SBRT) is increasingly used to manage spinal metastases, yet 
the technique’s eﬀ ectiveness in controlling the symptom burden of spinal metastases has not been well described. We 
investigated the clinical beneﬁ t of SBRT for managing spinal metastases and reducing cancer-related symptoms. 
Methods 149 patients with mechanically stable, non-cord-compressing spinal metastases (166 lesions) were given 
SBRT in a phase 1–2 study. Patients received a total dose of 27–30 Gy, typically in three fractions. Symptoms were 
measured before SBRT and at several time points up to 6 months after treatment, by the Brief Pain Inventory (BPI) 
and the M D Anderson Symptom Inventory (MDASI). The primary endpoint was frequency and duration of complete 
pain relief. The study is completed and is registered with ClinicalTrials.gov, number NCT00508443.
Findings Median follow-up was 15·9 months (IQR 9·5–30·3). The number of patients reporting no pain from bone 
metastases, as measured by the BPI, increased from 39 of 149 (26%) before SBRT to 55 of 102 (54%) 6 months after SBRT 
(p<0·0001). BPI-reported pain reduction from baseline to 4 weeks after SBRT was clinically meaningful (mean 3·4 
[SD 2·9] on the BPI pain-at-its-worst item at baseline, 2·1 [2·4] at 4 weeks; eﬀ ect size 0·47, p=0·00076). These improvements 
were accompanied by signiﬁ cant reduction in opioid use during the ﬁ rst 6 months after SBRT (43 [28·9%] of 149 patients 
with strong opioid use at baseline vs 20 [20·0%] of 100 at 6 months; p=0·011). Ordinal regression modelling showed that 
patients reported signiﬁ cant pain reduction according to the MDASI during the ﬁ rst 6 months after SBRT (p=0·00003), 
and signiﬁ cant reductions in a composite score of the six MDASI symptom interference with daily life items (p=0·0066). 
Only a few instances of non-neurological grade 3 toxicities occurred: nausea (one event), vomiting (one), diarrhoea (one), 
fatigue (one), dysphagia (one), neck pain (one), and diaphoresis (one); pain associated with severe tongue oedema and 
trismus occurred twice; and non-cardiac chest pain was reported three times. No grade 4 toxicities occurred. Progression-
free survival after SBRT was 80·5% (95% CI 72·9–86·1) at 1 year and 72·4% (63·1–79·7) at 2 years. 
Interpretation SBRT is an eﬀ ective primary or salvage treatment for mechanically stable spinal metastasis. Signiﬁ cant 
reductions in patient-reported pain and other symptoms were evident 6 months after SBRT, along with satisfactory 
progression-free survival and no late spinal cord toxicities.
Funding National Cancer Institute of the US National Institutes of Health. 
Introduction 
Almost 40% of patients with cancer develop spinal 
metastases during the course of their disease.1,2 In-
adequately treated spinal metastases can lead to pain and 
neurological complications, including metastatic epidural 
spinal cord compression. As a result, patients might 
experience severe symptom burden and diminished 
health-related quality of life (HRQoL).3–5
Palliative radiotherapy eﬀ ectively controls pain for 
patients with spinal metastases;4 however, higher-dose 
radiotherapy might be needed for durable tumour 
control and prevention of bony destruction of the spinal 
column, which results in spinal instability. The spinal 
cord’s sensitivity to radiation generally precludes high 
radiation doses to the spine or re-irradiation using 
conventional techniques.6 Accordingly, new techniques 
have been developed to optimise radiation dose delivery 
to bone metastases while sparing the spinal cord. 
Stereotactic body radiotherapy (SBRT), an emerging 
technique, uses image guidance to deliver high-dose 
radiation precisely, creating a steep dose gradient at the 
interface between spinal cord and tumour. This approach 
increases the therapeutic window by lowering the risk 
for spinal cord myelopathy.6–8 Delivered in high doses 
and one to ﬁ ve fractions, spinal SBRT is available on 
various platforms, some of which include CT image-
guided stereotaxy. SBRT can be used in combination 
with or in lieu of surgery and allows patients to avoid 
possible perioperative risk factors, such as general 
anaesthesia, bleeding, infection, or hospitalisation. 
Patients with late-stage cancer who are considering 
therapy options are often not informed about the 
symptom-reduction beneﬁ ts associated with a particular 
treatment. In a preliminary report of a prospective 
phase 1–2 trial of SBRT, we detailed the safety, eﬃ  cacy, 
and patterns of failure for SBRT using results from a 
Articles
396 www.thelancet.com/oncology   Vol 13   April 2012
subset of patients (n=63) with spinal metastases who were 
followed for up to 50 months.2 In the present analysis of 
the entire patient cohort, we investigated the symptom-
reduction beneﬁ t of spinal SBRT during the ﬁ rst 6 months 
post-treatment, and clinical beneﬁ t for up to 2 years. We 
hypothesised that, for patients with mech an ically stable 
spinal metastases, SBRT is a clinically eﬀ ective therapy 
for tumour control (evidenced by radio graphic depiction 
of tumour progression) and sympto matic improvement 
(evidenced by patient-reported outcomes). 
Methods
Patients 
This phase 1–2 trial was approved by the institutional 
review board of The University of Texas MD Anderson 
Cancer Center (Houston, TX, USA). Patients were 
accrued between Nov 6, 2002, and Jan 20, 2011, and all 
provided written informed consent before enrolling. 
Eligibility requirements included a diagnosis of cancer 
(excluding multiple myeloma), a Karnofsky performance 
status score of at least 40, and an MRI scan documenting 
spinal or paraspinal metastasis within 4 weeks of 
enrolment. Acceptable indications included oligometa-
static disease arising from a known primary tumour, 
failure of previous conventional external beam radio-
therapy or surgery, residual tumour after surgery, medical 
inoperability, and refusal to undergo surgery. A maximum 
of two distinct non-contiguous spinal metastases were 
allowed. Paraspinal tumours along the cervical, thoracic, 
or lumbar spine were included. The tumour could involve 
the vertebral column, but did not have to, nor did it need 
to enter the spinal canal. Patients receiving bis phos-
phonates or hormonal therapy were not excluded. 
Patients with mechanically unstable spine or epidural 
spinal cord compression were excluded; however, patients 
with previously documented spinal cord compression 
that had been decompressed and stabilised were eligible. 
Patients were excluded if they had a pacemaker, were 
unable to undergo MRI, or had received systemic radio-
therapy (strontium 89) or cytotoxic chemotherapy within 
30 days of enrolment, or spinal external beam radio-
therapy within 3 months of enrolment. 
Procedures
All patients underwent intensity-modulated, near-
simultaneous, CT-guided SBRT (CT-LINAC system 
[ExaCT targeting system, Varian Medical Systems, Palo 
Alto, CA, USA] or Trilogy treatment delivery systems 
with On-Board Imager Cone Beam CT [Varian Medical 
Systems]) using a BlueBAG BodyFIX Total Body 
immobilisation system (Elekta, Stockholm, Sweden), 
consisting of a whole-body vacuum cushion, carbon ﬁ bre 
base plate, and plastic ﬁ xation sheet. Stereotactic 
localisation and target-positioning frames were used 
(Integra-Radionics, Burlington, MA, USA). Patients 
received a total dose of 27–30 Gy, typically delivered in 
three fractions given every other day, with 10-Gy radiation 
volume received by the spinal cord limited to 0·01 cm³. 
Gross target volume encompassed the lesion as visualised 
on the pretreatment CT scan. The clinical target volume 
encompassed the gross target volume and surrounding 
vertebral body (including superior and inferior endplates 
and any existing paraspinal component), along with all 
additional spinal structures deemed to be at risk for 
recurrence, such as the pedicle, lamina, and posterior 
elements. In patients with postsurgical metallic artifacts 
near the area of interest, intrathecal contrast injection 
with iohexol (GE Healthcare Canada Inc, Mississauga, 
ON, Canada) was done 30–60 min before CT image 
acquisition to assist with accurate spinal cord delineation. 
Spinal MRI was done within 4 weeks of study enrolment 
and every 3 months thereafter. Baseline MRI was fused 
in many instances to assist in target delineation.
The primary endpoint was frequency and duration of 
complete pain relief. We measured pain at metastatic 
sites treated with SBRT via the Brief Pain Inventory 
(BPI).9 The BPI assesses pain at present and pain at its 
worst, least, and on average in the past 24 h, on a 
0–10 scale. At the same time, we measured general 
symptom burden via the M D Anderson Symptom 
Inventory (MDASI).10 The MDASI assesses 13 common 
cancer-related symptoms, including pain, and six 
symptom-interference items, each rated over a 24-h 
recall period on a 0–10 scale. A composite interference 
score was calculated as the mean of all six MDASI 
interference items for all patients. For the MDASI 
assessment, patients were instructed to rate their pain, 
but not their speciﬁ c pain at the spine site. The BPI and 
MDASI are well validated in patients with various types 
of cancer.9,10 The Medical Outcomes Study 12-Item Short-
Form Health Survey (SF-12) was administered as an 
HRQoL measure.11
Patient-reported symptoms were assessed in the clinic 
via the BPI, MDASI, and SF-12 pre-SBRT (baseline) and 
at 3 months and 6 months post-SBRT; assessments at 
2 weeks, 4 weeks, and 2 months were completed by the 
patient at home and returned by post, with a reminder 
call from a study nurse. 
MRI scans of the region treated were done at 3, 6, 9, 12, 
18, and 24 months post-SBRT and then every 6 months 
thereafter, as standard care. Lesions were classiﬁ ed as 
progressive (larger than at the previous assessment), 
stable (unchanged), or smaller by radiologists who were 
CNS specialists. These assessments were not time 
blinded. The radiologists’ reports were subsequently 
discussed by a multidisciplinary spine tumour board. 
History, neurological exam results, and McCormick 
functional classiﬁ cation12 were obtained at baseline and 
at each follow-up visit (during the same timepoints as 
patient-reported outcomes assessments). Clinical data 
including age, sex, tumour volume, and diagnosis were 
obtained at enrolment. Use of pain medication, Karnofsky 
per formance status, and metastatic tumour evaluation 
were also recorded at baseline and after SBRT. Opioid 
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use was documented as morphine equivalents. Toxicity 
was graded by the patient’s treatment team according to 
the National Cancer Institute Common Toxicity Criteria 
for Adverse Events, version 2.0.13 
Statistical analysis 
Descriptive statistics—mean, median, SD, and 
proportions—are used to describe patient and clinical 
characteristics. The patient, not the tumour, was the unit 
of analysis. For univariate testing, p values are two-tailed 
and considered signiﬁ cant if less than 0·05. To account 
for multiple comparisons in the symptom and HRQoL 
outcomes, which required eight modellings, we adjusted 
the individual type I error to be 0·05/8=0·00625 to 
maintain a conservative family-wise error rate of 0·05.
Using pain cutpoints established by Serlin and 
colleagues,14 we categorised ratings of the BPI’s pain-at-
its-worst item as no pain (0), mild pain (1–4), moderate 
pain (5–6), and severe pain (7–10). We tracked proportions 
of patients in each of these categories over time during 
the study. Concordance between BPI and MDASI pain-
at-its-worst ratings, both scored on a 0–10 scale in the 
past 24 h, was examined using paired t tests. Eﬀ ect sizes 
were calculated to estimate the magnitude of change in 
BPI and MDASI ratings (composite score for all patients) 
between baseline and 4 weeks post-treatment.15,16 For 
patient-reported outcomes measures, eﬀ ect sizes are 
clinically meaningful at roughly one-half SD or higher, 
the level often used in distribution-based methods of 
determining meaningful diﬀ erences.17 Lowess curves,18 
which represent a smoothed estimate of average MDASI 
symptom severity and interference as a function of time, 
were constructed from baseline to 6 months post-SBRT. 
Ordinal regression models19 and generalised linear 
mixed models were ﬁ tted to examine symptom develop-
ment for the ﬁ ve most-severe MDASI symptoms and the 
symptom-interference component score from baseline to 
6 months post-SBRT. Individual symptom scores were 
treated as ordinal responses. Independent variables 
included weeks from start of therapy, age, sex, tumour 
volume of spinal metastasis at baseline, type of primary 
cancer, disease progression status 6 months after SBRT 
based on radiographic (spinal MRI) results, opioid use, 
and Karnofsky performance status at baseline.
Progression-free survival (PFS) and overall survival 
curves from date of enrolment were generated using the 
Kaplan-Meier method. Patient survival information was 
obtained from a retrospective review of medical records. 
Statistical analysis was done using SPSS version 17.0 
and  SAS version 9.2. This study is registered with 
ClinicalTrials.gov, number NCT00508443.
Role of the funding source
Neither the National Cancer Institute nor the National 
Institutes of Health had any role in the study design, 
data collection, analysis, interpretation, or preparation of 
the report. The authors were responsible for the design 
of the trial. XSW, IG, PL, PKA, and ELC had access to the 
raw data. The corresponding author had ﬁ nal respon-
sibility for the decision to submit for publication.
Results
Table 1 shows patient demographic and clinical charac-
teristics. Of the 184 patients approached and consented, 
35 did not provide symptom data and thus were 
unevaluable. The remaining 149 patients, with 166 spinal 
metastases at cervical, thoracic, or lumbar vertebral levels, 
were included in the analysis. 17 of 149 patients had two 
distinct spinal metastasis sites treated in the same session, 
and 34 of 149 (23%) were receiving bisphosphonates at 
enrolment. Spinal MRIs were done for 142 of 149 patients 
(95%) at the 6-month follow-up.
Baseline characteristics (N=149)
Number of lesions 166
Age in years  
Mean (SD) 56·4 (12·5)
Median (range) 58·0 (20·0–88·0)
Sex
Male 77 (52%)
Female 72 (48%)
Karnofsky performance status 
100 8 (5%)
80–90 108 (72%)
70 30 (20%)
<70 3 (2%)
Previous therapy to spinal site
Radiotherapy alone 40 (27%)
Surgery alone 22 (15%)
Radiotherapy and surgery 39 (26%)
None 48 (32%)
Primary histology
Breast cancer 15 (10%)
Colon cancer 6 (4%)
Non-small-cell lung cancer 15 (10%)
Melanoma 4 (3%)
Thyroid cancer 14 (9%)
Renal cancer 47 (32%)
Sarcoma 17 (11%)
Other 28 (19%)
Unknown 3 (2%)
SBRT site 
Cervical 28 (19%)
Thoracic 66 (44%)
Lumbar 51 (34%)
Sacral 4 (3%)
Metastatic tumour volume in cm³, 
median (range)
38·2 (1·6–357·9)
Data are number of patients (%) unless otherwise stated. SBRT=stereotactic body 
radiotherapy.
Table 1: Patient demographic and clinical characteristics
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At the time of analysis, 40 of 149 patients (27%) were 
still alive, with a median follow-up of 15·9 months (range 
1·0–91·6; IQR 9·5–30·3) and mean 20·9 months 
(SD 17·1). Median overall survival was 23 months 
(95% CI 18·6–27·2) post-SBRT, with 1-year and 2-year 
actuarial survival of 68·5% (60·1–75·4) and 46·4% 
(37·8–54·7), respectively. Tumour progression was seen 
in 41 of 149 patients (28%) and occurred at a median of 
13 months (range <1–101), based on MRI scans. Actuarial 
PFS based on MRI scans at 6 months, 1 year, and 2 years 
post-SBRT was 86·1% (95% CI 79·4–90·7), 80·5% 
(72·9–86·1), and 72·4% (63·1–79·7), respectively. 
Figure 1 shows the proportion of patients with no 
pain to severe spinal pain, according to the BPI’s 
pain-at-its-worst ratings, at baseline and post-SBRT 
assessments. We noted signiﬁ cant reductions in the 
severity of patient-reported pain between baseline and 
4 weeks post-treatment (mean of 3·4 [SD 2·9] at baseline, 
2·1 [2·4] at 4 weeks on the BPI’s pain-at-its-worst item 
[0–10 scale]; eﬀ ect size 0·47, p=0·00076), and between 
baseline and 6 months post-SBRT (mean 3·4 [SD 2·9] at 
baseline, 1·7 [2·4] at 6 months; eﬀ ect size 0·64, p<0·0001). 
The proportion of patients reporting no spine pain on 
the BPI increased signiﬁ cantly between baseline and 
4 weeks post-SBRT, from 39 of 149 (26%) to 43 of 
109 (39%) (p=0·038). This improvement continued 
throughout the study, with 53 of 120 (44%) reporting no 
pain at 3 months (p=0·004) and 55 of 102 (54%) reporting 
no pain at 6 months (p<0·0001). Further, a signiﬁ cant 
decrease in the percentage of patients with moderate-to-
severe BPI spine pain (rated ≥5 on the 0–10 scale) was 
noted from baseline to 4 weeks (p=0·003), 2 months 
(p<0·0001), and 6 months (p=0·002) post-SBRT.
We noted clinically meaningful reductions in mean 
MDASI pain ratings between baseline and 4 weeks post-
treatment (from 3·4 [SD 3·1] at baseline to 2·1 [2·6] at 
4 weeks on the MDASI’s 0–10 scale; eﬀ ect size 0·47). 
Diﬀ erences in mean pain severity ratings between the 
BPI (metastatic bone pain) and MDASI (general pain) 
were noted only for the 6-month assessment (p=0·022; 
table 2). We noted signiﬁ cant reduction in opioid use 
from baseline to 3 months (p=0·021) and baseline to 
6 months (p=0·011) post-SBRT (table 2). 
During the 6 months of observation, the ﬁ ve most severe 
MDASI symptoms were fatigue, pain, disturbed sleep, 
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Figure 1: Percentage of patients with no, mild, moderate, or severe pain on the BPI 0–10 scale, before and after SBRT
BPI=Brief Pain Inventory. SBRT=stereotactic body radiotherapy.
BPI pain-at-its-worst score (0–10)* MDASI pain score (0–10)* Strong opioid 
use† 
n Mean score (SD) n Mean score (SD) n (%)
Baseline 148 3·4 (2·9) 148 3·4 (3·1) 43 of 149 (28·9%) 
2 weeks 124 2·9 (2·8) 124 2·9 (3·0) 34 of 121 (28·1%) 
4 weeks 109 2·1 (2·4) 109 2·1 (2·6) 26 of 110 (23·6%)
2 months 108 2·3 (2·6) 108 2·3 (2·7) 23 of 105 (21·9%)
3 months 120 2·1 (2·7) 120 2·1 (2·8) 31 of 121 (25·6%)
6 months 102 1·7 (2·4) 102 1·9 (2·5) 20 of 100 (20·0%)
SBRT=stereotactic body radiotherapy. BPI=Brief Pain Inventory. MDASI=M D Anderson Symptom Inventory. 
*No signiﬁ cant diﬀ erences between BPI pain-at-its-worst mean scores and MDASI pain item mean scores (paired t tests) 
were found at any timepoint other than the 6-month assessment (p=0·022). †The number of patients for whom 
analgesia data were available diﬀ ered slightly from the number of patients who provided symptom data.
Table 2: Pain severity scores and opioid use over time, before and after SBRT 
Articles
www.thelancet.com/oncology   Vol 13   April 2012 399
drowsiness, and distress. Figure 2 shows the smoothed 
estimate of average severity of each symptom over time 
using Lowess curves, with the week of SBRT completion 
shown as week 0. The Lowess curves in ﬁ gure 2 show that 
symptom interference lessened over time.
Table 3 gives p values from ordinal regression 
modelling of MDASI symptom severity and interference, 
and SF-12 physical and mental health component 
scores, adjusted for independent variables. Patients 
reported signiﬁ cant pain reduction (p=0·00003) 
6 months after SBRT, and signiﬁ cant reduction in 
disturbed sleep, drowsiness, sadness (all p<0·0001), 
fatigue, distress, lack of appetite, nausea, and diﬃ  culty 
remembering (all p<0·05). We observed no signiﬁ cant 
change over time for physical or mental health com-
ponent scores. Ordinal regression modelling showed 
that a composite score of all six interference items 
decreased signiﬁ cantly at each successive assess ment 
during the 6 months after SBRT (p=0·0066). 
Patients whose lesions were categorised as progressive 
at the 6-month follow-up examination (19 of 149; 13%) 
reported signiﬁ cantly more-severe MDASI pain 
(p<0·0001), fatigue (p=0·01), and drowsiness (p=0·00008) 
than did patients with stable or smaller lesions. Patients 
who received opioids during the 6 months after SBRT 
reported more severe MDASI pain, fatigue (both 
p<0·0001), disturbed sleep, distress, and drowsiness 
(all p<0·001) than did patients not using opioids. 
Mild toxic eﬀ ects were documented during the study, 
including grade 1 and 2 transient numbness and tingling, 
nausea, and vomiting. Grade 3 toxicities were nausea 
(one event), vomiting (one event), diarrhoea (one event), 
fatigue (one event), non-cardiac chest pain (three events), 
dysphagia (one event), neck pain (one event), diaphoresis 
(one event), and pain associated with severe tongue 
oedema and trismus (two events). No grade 4 toxicities 
were reported, and we observed no radiation-related 
spinal cord myelopathy during the study. 
Discussion 
This study incorporated validated single-symptom (BPI) 
and multisymptom (MDASI) assessments to measure 
patient-reported outcomes for pain and other symptoms 
in patients with metastatic spine lesions who received 
SBRT. In accordance with our previous report docu-
menting the safety, eﬀ ectiveness, and patterns of failure 
of spinal SBRT,2 here we showed signiﬁ cant reductions 
in the severity of pain and consistent reductions in other 
patient-reported symptoms and symptom interference 
6 months after spinal SBRT, along with satisfactory PFS 
and no late spinal cord toxicities. 
In a retrospective review, Sheehan and colleagues20 
found that pain was the most common presenting 
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Figure 2: Lowess curves of symptom severity (A) and symptom interference 
(B) on the MDASI 0–10 scale, before and after SBRT
MDASI=M D Anderson Symptom Inventory. SBRT=stereotactic body 
radiotherapy. n=number of patients. *Assessment timepoint.
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symptom from spinal metastases. Our results show that 
SBRT is an eﬀ ective treatment for metastatic spinal pain 
in patients with late-stage cancer. Between baseline and 
4 weeks post-SBRT, we observed medium, but clinically 
meaningful, eﬀ ect sizes for pain reduction as reported 
on both the BPI pain-at-its-worst and MDASI pain 
items, along with signiﬁ cant increase in the number of 
patients reporting complete pain relief as early as 
4 weeks post-SBRT. Signiﬁ cant improvement in BPI 
pain ratings and eﬀ ect size relative to pre-SBRT scores 
was even larger 6 months after treatment (eﬀ ect 
size 0·64, p<0·0001), when only two patients had 
tumour progression and high pain severity and were 
receiving opioid therapy. The eﬀ ectiveness of SBRT for 
tumour and pain control was further evidenced by a 
reduction over time in the use of strong opioids, 
a standard of care for managing severe pain. 
Patient-reported data from the BPI and the MDASI, 
which use the same 0–10 pain-severity rating scale and 
24-h recall period (table 2), did not diﬀ er signiﬁ cantly in 
this cohort of patients with advanced cancer. This result 
suggests that researchers can use either scale in clinical 
studies when pain at its worst is the outcome of interest, 
and the same rating is expected with either scale. 
However, the MDASI measures a broader array of critical 
symptoms and has modules tailored to speciﬁ c treatments 
and types of cancer. 
The present study shows that pain reduction and 
functional improvement can also be reﬂ ected in the 
reduction of associated symptoms, such as fatigue, 
distress, and disturbed sleep.21 Using a sensitive multiple-
symptom assessment method (the MDASI) with a highly 
selective but comprehensive set of symptom items,22,23 we 
not only prospectively identiﬁ ed pain and other major 
symptoms in a cohort of patients who received spinal 
SBRT, but also showed how multiple symptoms improved 
over time after treatment. Frequent measurement allowed 
us to capture the quick response to SBRT and its durability 
over time. Signiﬁ cant reductions in the severity of several 
MDASI symptom models* MDASI symptom 
interference model 
(composite 
interference score)
HRQoL models 
(SF-12 component 
scores)
Pain Fatigue Distress Disturbed 
sleep
Drowsiness Physical Mental 
health
Weeks of treatment 0·00003† 0·03651 0·00493† 0·00008† 0·00005† 0·0066 0·28 0·47
Age 0·59 0·85 0·36 0·06 0·28 0·47 0·16 0·98
Sex (female vs male) 0·00214 0·00298 0·00461 0·02484 0·03328 0·07 0·12 0·0347
Metastatic tumour volume 0·78 0·71 0·30 0·93 0·91 0·40 0·97 0·98
Diagnosis (lung vs renal) 0·97 0·20 0·15 0·56 0·25 0·16 0·25 0·58
Progression status at 6 months 
(failure vs no failure)
<0·0001† 0·0104 0·05 0·09 0·00008† 0·0022† 0·0001† 0·65
Opioid use over 6 months <0·0001† <0·0001† 0·0004† 0·00364† 0·0004† 0·0001† <0·0001† 0·06
Baseline Karnofsky performance status 0·72 0·08 0·0073 0·67 0·29 0·0003† 0·0002† 0·033
Signiﬁ cance testing was done by mixed-eﬀ ect regression analysis. Results shown are p values. SBRT=stereotactic body radiotherapy. MDASI=M D Anderson Symptom 
Inventory. HRQoL=health-related quality of life. *Ordinal regression modelling was done for each of the ﬁ ve most severe MDASI symptoms to assess development over time. 
†Signiﬁ cant at p<0·00625, after adjusting for multiple comparisons (eight models).
Table 3: Signiﬁ cance of reduced score for patient-reported outcomes during the ﬁ rst 6 months after SBRT, adjusted for independent variables
Panel: Research in context
Systematic review
In recent years, spinal stereotactic body radiation therapy (SBRT) has become an 
increasingly established technique for the management of spinal metastases; however, 
when this phase 1–2 trial was designed and activated in 2002, spinal SBRT literature was in 
its infancy, consisting of preliminary technical reports with sparse outcomes data. 
Accordingly, initial analyses of patients treated on this protocol focused on feasibility, 
safety, and tumour-control outcomes. Over the past decade, data from this patient cohort 
and from other studies8 have contributed to the continued emergence of spinal SBRT for 
management of spinal metastases. However, there remains a relative paucity of literature 
describing the eﬀ ectiveness of spinal SBRT in controlling the symptom burden of spinal 
metastases. Drawing on previous experience in symptom research,25,26 we applied 
well-established symptom-assessment methods to analyse outcomes data acquired from 
our prospective cohort.
Interpretation
The results of this study show that SBRT is an eﬀ ective primary or salvage treatment for 
mechanically stable spinal metastasis. Multiple symptoms were assessed simultaneously 
and longitudinally for each patient and compared with baseline, with each patient serving 
as his or her own control. Signiﬁ cant reduction in patient-reported pain and other 
symptoms was evident 6 months after SBRT, along with satisfactory progression-free 
survival and no late spinal cord toxicities. For patients with evidence of tumour 
progression 6 months after SBRT, such progression was signiﬁ cantly associated with 
more severe pain, as expected, suggesting a true (non-placebo) palliative eﬀ ect for SBRT. 
This trial provides prospective data that support the careful use of spinal SBRT in selected 
patients, since SBRT safely and reliably halts the progression of disease while reducing 
patient symptoms and improving functioning in daily life, as measured by validated 
methods. This study also highlights the importance of integrating patient-reported 
symptom assessments with clinical outcome evaluations to fully demonstrate the beneﬁ t 
of SBRT in patients with metastatic spinal disease. The ongoing Radiation Therapy 
Oncology Group 0631 randomised trial is investigating this question. 
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symptoms in addition to metastatic pain suggest that 
spinal SBRT produces minimum symptom burden and 
toxic eﬀ ects for patients with late-stage cancer. Renal-cell 
carcinomas that metastasise to the spine are among the 
most diﬃ  cult to control and therefore are most often 
referred for spinal SBRT. We did not ﬁ nd a signiﬁ cant 
diﬀ erence between renal-cell carcinoma and other 
primary histologies on patient-reported severity of any 
MDASI symptom (data not shown).
Fatigue was consistently the most severe symptom over 
time, possibly as a result of advanced disease and 
continuous use of opioids. Although fatigue improved 
over the 6 months post-SBRT (p=0·037), the physical and 
mental health component scores of the SF-12 remained 
more or less constant in follow-up. These results are 
consistent with those of Degen and colleagues,24 who 
reported signiﬁ cant pain reduction 4 weeks after spinal 
SBRT that was durable to 1 year, but no signiﬁ cant change 
in physical or mental well-being data from the SF-12. In 
the present study, lower baseline Karnofsky performance 
status was signiﬁ cantly associated with higher total 
symp tom interference on the MDASI and worsening 
physical well-being as measured by the SF-12 (table 3). 
The eﬃ  cacy and safety of SBRT we report in this study 
are supported by the structured schedule with deﬁ ned 
assessment intervals and follow-up serial spinal MRIs, 
which permitted close assessment of the procedure. MRI 
scans, obtained for 95% of study participants, showed a 
PFS of over 80% 1 year after SBRT. This result is similar to 
results reported by other investigators8 and shows that 
spinal SBRT is an eﬃ  cacious primary or salvage treatment 
of metastatic tumours of the spine. In this study, SBRT 
did not lead to any radiation-related spinal cord myelopathy; 
the numbness reported by some patients was probably 
caused by pre-SBRT chemotherapy. Only a few instances 
of non-neurological grade 3 toxicities (nausea, vomiting, 
diarrhoea, and fatigue) and no grade 4 toxicities occurred. 
Patient compliance and missing data can be an issue in 
prospective studies. We observed a random missing 
pattern in the data. Ordinal regression modelling, which 
accounts for repeated measurements over time, allowed 
us to maximise use of the available data in a longitudinal 
fashion. No missing data imputation was performed in 
this modelling step. In the present study, 24 patients did 
not return their paper-and-pencil symptom assessment 
results by post at the 2-week assessment timepoint; 
nonetheless, most of these patients contributed symptom 
data at subsequent timepoints. One possibility for 
reducing the rate of random missing patient-reported 
outcomes is to have study staﬀ  conduct symptom surveys 
over the phone. 
One limitation of this study is the absence of a control 
group against which to measure the eﬀ ect of SBRT on 
symptom development. However, it is well accepted that 
SBRT has a quantiﬁ able clinical eﬀ ect on tumour growth 
with an accompanying reduction in pain at the radiation 
site, as shown in our previous report in a subset of this 
cohort of patients with stage IV cancer.2 One strength of 
the present study is that multiple symptoms were 
assessed simultaneously and longitudinally for each 
patient and compared with baseline, with each patient 
serving as his or her own control. Tumour progression 
6 months after SBRT was signiﬁ cantly associated with 
more-severe pain, as expected, suggesting a true (non-
placebo) palliative eﬀ ect. An even higher level of evidence 
could be provided by a randomised trial comparing 
stereotactic radiation with conventional radiation. Such a 
trial is currently ongoing with the Radiation Therapy 
Oncology Group 06-31 study.
In reviewing patient records, we found that 16 patients 
were positive for adrenal metastasis and 12 were positive 
for brain metastasis at enrolment. For this reason, 
although the protocol designated data collection up to 
24 months, we did not use patient-reported outcomes 
data beyond 6 months, after which the symptom-
reduction beneﬁ t from SBRT could be confounded by 
increased pain from rapid disease progression at or near 
the end of life in this cohort with very advanced cancer. 
Further study of this data is warranted to determine the 
entire proﬁ le of pain and other symptoms, from beyond 
6 months post-SBRT to near the time of death. 
The role of SBRT in treating mechanically stable spinal 
metastases without spinal cord compression is continuing 
to develop in an era in which new tech nologies and 
treatments are being highly scrutinised. Most patients 
with spinal metastases can still beneﬁ t from conventional 
palliative radiation therapy. Surgery or vertebral 
augmentation with cement should be considered for 
stabilising patients with mechanically unstable spines 
before proceeding to radiation therapy. Nonetheless, the 
current study provides additional data that support the 
clinical beneﬁ t of SBRT for carefully selected patients 
and suggests that SBRT reliably halts the progression of 
disease, reduces patient symptoms, and leads to improved 
functioning in daily life—thus demonstrating both 
symptomatic and clinical beneﬁ t (panel). This study also 
highlights the importance of integrating patient-reported 
symptom assessments with clinical outcome evaluations 
to fully demonstrate the beneﬁ t of SBRT in patients with 
metastatic spinal disease. 
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